An Open Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors

Trial Profile

An Open Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2015

At a glance

  • Drugs BAY 794620 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Jan 2013 Planned End Date changed from 1 Jan 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 11 Jan 2012 Planned end date changed from 1 Feb 2013 to 1 Jan 2013 as reported by ClinicalTrials.gov (NCT01028755).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top